Hero Finding
Clinical chemistry laboratories were more than twice as likely as immunoassay laboratories to be running at 60 to 80% of instrument capacity, a separation that held under significance testing.
Across all 257 laboratories, a majority were running their primary instrument category at 60% of capacity or above. For a consumables category whose demand tracks test throughput, that bounds how much volume growth the installed base can absorb. The category-level cuts are where the separation lives: clinical chemistry ran closest to saturation, immunoassay ran loosest, and the gap tested significant against both immunoassay and the other-instruments group.
Share of laboratories at 60 to 80% instrument utilization, by test category · indexed to peak = 100 · indexed · blinded values
Key Findings
What the utilization data established.
Five signals set the shape of the market-entry model. Each was read at the instrument-category level rather than for the category as a whole, which is what the hard quotas were built to allow.
The aggregate market runs hot: 56% of laboratories at or above 60% utilization.
Across all 257 laboratories, 40% sat in the 60 to 80% band, 16% at 80 to 100%, and only 4% below 20%. For a consumables category whose demand tracks test throughput, that distribution establishes a market with limited slack: it bounds how much volume growth the installed base can absorb without new instrument capacity.
Clinical chemistry runs closest to saturation, and the separation is statistically real.
Clinical chemistry was the most heavily utilized category, and the result tested significant against both immunoassay and the other-instruments group. Immunoassay ran loosest. Clinical chemistry laboratories were more than twice as likely as immunoassay laboratories to sit in the 60 to 80% band, which reshapes where consumable demand growth can actually come from.
Inside North America, the category separation sharpens.
The clinical chemistry North America cell ran hottest of the ten category-geography cells and tested significant against four of the five other North American category cells. The regional cut sharpened the category story rather than diluting it: the same category leads in the largest market, with the statistical separation intact.
Category separation exceeded regional separation on every read.
EU5 laboratories sat marginally higher in the 60 to 80% band than North American ones, 46% against 38%, but the difference did not carry the significance that the category splits did. For the sizing model that was a useful negative: geography can be treated as a scaling factor, while test category has to be modelled as a distinct segment.
Consistency flags protected the forward bands, the most leveraged inputs in the model.
Twenty-six responses carried internally inconsistent utilization and trend combinations: a category already at 80 to 100% reporting continued sharp increases, or one below 20% reporting sharp decreases. The flags isolated them for review before the base was locked, rather than letting them distort the forward-looking bands a three-year sizing model leans on hardest.
The categories carrying the most current throughput hold the least room for demand growth.
Going in, a volume-led read pointed the model at clinical chemistry, the category with the heaviest utilization and substantial current throughput. The utilization layer inverted that: growth in a saturated category requires new instrument capacity before consumable demand can move, while the loosest categories can absorb volume on installed instruments. A model built on today's volume alone would have pointed at clinical chemistry; the utilization layer points somewhere different.
I also expect increasing demand for third-party controls that work properly across multiple instrument platform to reduce the cost and vendors combining high quality products with excellent scientific support and reliable supplies will have, in my opinion, a clear competitive advantage.
Laboratory Director · Clinical Reference Laboratory · EU5
Study Design
N=257lab decision-makers
4 institution types
7 countries
5 instrument categories under hard quota
Banded single-select measures carried the quantitative sizing: utilization, volume, spend and price, each captured on matched historical and forward three-year horizons from the same respondent. Adaptive probing captured selection and switching drivers in the respondents' own words. Every reported base was reconciled to the locked 257 profile before the 11-page executive report and 88-page data appendix were sealed client-final.
Sample by segment
Mix
What the guide covered
- Current instrument utilization, with historical and expected three-year change on matched bands
- QC / reference-material spend and price trend, historical and forward three-year
- Instrument-brand versus third-party sourcing split at three points in time
- Vendor selection criteria, purchasing construct, and switching triggers
- Unaided vendor recall, capped at five names, and a vendor relationship matrix
- Price sensitivity: the discount threshold that would prompt a vendor switch
Who qualified
- Laboratory directors, managers, and equivalent decision-makers or influencers over QC / reference-material vendor selection
- Laboratories running 500 or more diagnostic tests per day
- Hospital labs 116 · clinical reference labs 71 · LDT and specialty reference 36 · CRO central labs 34
- North America 190 · EU5 67 · instrument category crossed with each geography under quota
- Per-interview QC scoring with removal review, reconciled across four expert networks
Crosstab · Utilization by Category
The 60 to 80% utilization band by instrument category.
Share of laboratories at 60 to 80% instrument utilization, by test category, indexed to the peak category = 100. Highlighted row = the category running closest to saturation. Bases are the hard-quota category cells within the 257 profile.
| 60 to 80% band (indexed) | Category base (n) | |
|---|---|---|
| Clinical Chemistry | 100 | 58 |
| Hematology | 82 | 49 |
| Molecular Diagnostics | 75 | 54 |
| Immunoassay | 46 | 50 |
| Other instruments | 42 | 46 |
Indexed · blinded values · Clinical chemistry vs immunoassay · significant · Clinical chemistry vs other instruments · significant · NA clinical chemistry cell hottest · significant against 4 of 5 peer cells · N=257 · 5 hard-quota categories
Voice of the Laboratory
How laboratory decision-makers described the buying logic.
Verbatims from the qualitative layer, selected to span institution types, instrument categories and regions.
“Unless some issue comes, supply chain or lack of availability or, you know, those issues. Then we go and look for the other vendors. Otherwise, we always prefer to buy the QC reference material for the same brand of the instrument.”
“Lot quality, lot to lot consistency, and reliable supply remain the key factor vendor selection. Price is important, but it is generally secondary to quality and regulatory compliances.”
“While price is important, product quality lot-to-lot consistency, and dependable technical support, typically have a greater impact on purchasing decisions. Because switching QC vendors requires validation, and can affect laboratory workflow.”
“I would say, you know, one trend worth highlighting is that laboratories are looking beyond the price at this point and placing greater emphasis on the overall value. Right now, we're looking more for a consistent technical performance.”
“The larger the number of analytes per QC material the better for efficient workflow.”
Implications · what the evidence supports
Three readings from the research.
What the market-sizing model carried forward, grounded in the utilization layer and the category-level bases behind it.
Consumable demand growth is capacity-bounded in aggregate.
With 56% of laboratories at or above 60% utilization and only 4% below 20%, throughput growth on the installed base is constrained. A sizing model that assumes testing volume expands freely on current instruments overstates the near-term opportunity; the base case the data supports models demand against the utilization ceiling, category by category.
Entry sequencing is a test-category question.
Category separation exceeded regional separation on every read. The categories with the most instrument headroom are the ones where test volume can grow without a capital purchase, and clinical chemistry, the most saturated category, carries the least of that headroom despite substantial current throughput. A model built on today's volume alone would have pointed at clinical chemistry; the utilization layer points somewhere different.
Geography behaves as a scaling factor in the model.
The EU5 versus North America difference in the upper utilization band stayed inside the category spread and did not carry significance. The structure the data supports treats regional totals as a multiplier on market size while test category carries the segmentation, which keeps the model runnable per category cell, the way the bases were built.
Signals the data flagged
- Clinical chemistry utilization tested significant against immunoassay and the other-instruments group
- The clinical chemistry North America cell tested significant against four of five peer cells
- Regional separation stayed inside category separation across the sample
- 26 internally inconsistent responses isolated before the forward bands were modelled
Risks the data surfaced
| Aggregate utilization ceiling caps near-term consumable volume growth | High |
| Saturated categories need new instrument capacity before demand can move | Med |
| Forward three-year bands are respondent-expected, with no prior wave to benchmark | Med |